Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
A/T/S vs BIAXIN XL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Treatment of acne vulgaris (FDA-approved indication),Treatment of bacterial infections caused by susceptible organisms (off-label use for acne is the primary use)
Acute bacterial exacerbation of chronic obstructive pulmonary disease,Acute maxillary sinusitis,Community-acquired pneumonia,Pharyngitis/tonsillitis caused by Streptococcus pyogenes,Uncomplicated skin and skin structure infections,Mycobacterium avium complex infection (prevention and treatment),Helicobacter pylori infection (in combination with other drugs)
Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.
500 mg orally once daily for 7 to 14 days
Terminal elimination half-life: 1–2 hours (prolonged in hepatic impairment).
Terminal elimination half-life is 5-7 hours in healthy adults; prolonged to 20-40 hours in patients with severe hepatic impairment (Child-Pugh Class C).
Antithrombin is a glycoprotein; its metabolism involves cellular uptake and catabolism, but specific CYP450 enzymes are not involved. Degradation occurs via proteolysis and reticuloendothelial system clearance.
Primarily metabolized by the cytochrome P450 system, mainly CYP3A4, to active metabolites such as 14-hydroxyclarithromycin.
Renal: 10-20% (active drug and metabolites); Fecal: minimal; Biliary: not significant.
Approximately 20-30% of the dose is excreted unchanged in urine, with the remainder as metabolites (primarily via biliary/fecal elimination). Renal clearance accounts for about 12% of total clearance.
70-90% bound to serum albumin.
Approximately 70% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
0.5–0.8 L/kg (low Vd, minimal tissue penetration).
Volume of distribution is 3-4 L/kg, indicating extensive tissue penetration (e.g., lungs, sinuses, tonsils).
Topical: 1–5% (minimal systemic absorption).
Oral bioavailability is approximately 50% due to first-pass metabolism; food does not significantly affect the extended-release formulation.
No specific adjustment required; drug is not renally eliminated.
Cr Cl <30 m L/min: 500 mg orally once daily or 250 mg twice daily. Cr Cl <30 m L/min not recommended for BIAXIN XL due to decreased clearance.
No specific adjustment; antithrombin is produced in the liver, but exogenous replacement does not require dose adjustment in hepatic impairment.
Child-Pugh Class C: reduce dose by 50% or consider alternative therapy. Child-Pugh Class A or B: no adjustment necessary.
Dosing based on weight and antithrombin levels; typical initial dose 30-50 IU/kg, followed by maintenance to achieve target levels. Clinical trial data limited in neonates.
Not approved for use in children less than 12 years of age. For children ≥12 years: same as adult dosing.
No specific adjustment; use standard dosing with monitoring of antithrombin activity and bleeding risk.
Increased risk of QT prolongation. Monitor renal function and consider dose adjustment based on creatinine clearance. No specific dose adjustment is recommended solely for age.
None.
No FDA boxed warning.
Hypersensitivity reactions including anaphylaxis have occurred.,Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Use with caution in patients with hepatic impairment.,Potential for QT prolongation and ventricular arrhythmias, especially with intravenous administration or concomitant drugs that prolong QT interval.
Increased risk of cardiac arrhythmias (QT prolongation, torsades de pointes) in patients with pre-existing cardiac conditions or electrolyte abnormalities,Hepatotoxicity, including hepatic failure and jaundice,Exacerbation of myasthenia gravis symptoms,Increased risk of colchicine toxicity when used with P-glycoprotein inhibitors,Potential for drug interactions due to CYP3A4 inhibition
Hypersensitivity to erythromycin or any macrolide antibiotic.,Use with caution in patients with pre-existing QT prolongation or electrolyte abnormalities (relative contraindication).
Hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic,Concomitant use with ergotamine or dihydroergotamine,Concomitant use with HMG-Co A reductase inhibitors that are extensively metabolized by CYP3A4 (e.g., lovastatin, simvastatin),Concomitant use with pimozide,History of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use,QTc prolongation or cardiac arrhythmia history (relative contraindication)
No specific food interactions. Avoid excessive alcohol consumption as it may increase skin dryness.
Take with food to enhance absorption and reduce GI intolerance. Avoid grapefruit and grapefruit juice as they may alter drug metabolism. No other significant food interactions.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk to fetus is low across all trimesters.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but maternal toxicity at high doses produced fetal malformations. Second and third trimesters: No known fetal risks from limited human studies; however, due to rare reports of pyloric stenosis in infants exposed to macrolides late in pregnancy, consider risk-benefit. Overall, use only if clearly needed.
Compatible with breastfeeding. Erythromycin is excreted into breast milk in small amounts (M/P ratio approximately 0.5). Topical use results in negligible systemic exposure; unlikely to cause adverse effects in nursing infants.
Clarithromycin is excreted into breast milk. M/P ratio is approximately 1.0 (based on total drug). Consider the potential for infant gastrointestinal effects (diarrhea, candidiasis) and theoretical risk of antibiotic-associated colitis. Compatible with breastfeeding with monitoring for adverse effects in the infant.
No dose adjustment required. Systemic absorption from topical application is minimal and not significantly altered by pregnancy-related pharmacokinetic changes.
No specific dose adjustments are recommended for pregnancy; however, pharmacokinetic changes (increased volume of distribution, altered clearance) may occur, but clinical significance is not established. Use standard adult dosing with caution.
A/T/S (erythromycin 2% topical solution) is indicated for acne vulgaris. Avoid contact with eyes, mouth, and mucous membranes. May cause skin dryness or irritation; use moisturizer. Effectiveness may decrease with prolonged use due to bacterial resistance. Not recommended for use with other topical erythromycin products or clindamycin to avoid antagonism.
BIAXIN XL (clarithromycin extended-release) is a macrolide antibiotic with a long half-life allowing once-daily dosing. It is a strong CYP3A4 inhibitor, increasing levels of many drugs including statins, warfarin, and oral contraceptives. Prolongs QT interval; avoid in patients with known QTc prolongation or concurrent use of other QT-prolonging agents. Common adverse effects include metallic taste and gastrointestinal upset. Monitor liver function in hepatic impairment.
Apply a thin layer to affected areas twice daily after washing.,Avoid contact with eyes, lips, and mouth; if contact occurs, rinse thoroughly with water.,May cause stinging, burning, or peeling; if irritation persists, consult your doctor.,Use sunscreen daily as this medication may increase sensitivity to sunlight.,Do not use more than prescribed; overuse may increase side effects without improving results.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep away from open flames or heat sources; product is flammable.
Take with food to reduce stomach upset.,Do not crush or chew the tablet; swallow whole.,Complete the full course even if you feel better.,Avoid alcohol during treatment.,Inform your doctor about all medications, including OTC and herbal supplements, due to drug interactions.,Report symptoms of arrhythmia (dizziness, palpitations, fainting) or severe diarrhea.,May cause metallic taste; this is temporary.,Use alternate contraception if on oral contraceptives due to interaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about A/T/S vs BIAXIN XL, answered by our medical review team.
A/T/S is a Macrolide antibiotic that works by A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.. BIAXIN XL is a Macrolide Antibiotic that works by Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between A/T/S and BIAXIN XL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of A/T/S is: Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.. The standard adult dose of BIAXIN XL is: 500 mg orally once daily for 7 to 14 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between A/T/S and BIAXIN XL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. A/T/S is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk . BIAXIN XL is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but maternal toxicity at high doses produced fetal ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.